

**Supplementary Table 2.** Metrics for days of medication use among the follow-up days within 1 calendar year

Medication	Median (interquartile range)	Range (%)
Metformin	56.8 (48.7–60.6)	38.4–65.9
Dipeptidyl peptidase-4 inhibitor	24.8 (4.4–39.3)	0–40.1
Glucagon-like peptide-1 receptor agonist	0.1 (0–0.8)	0–2.7
Sodium-glucose cotransporter-2 inhibitor	0.1 (0–6.0)	0–19.1
Secretagogues	31.6 (28.6–43.1)	26.5–54.6
$\alpha$ -Glucosidase	1.9 (0.6–6.4)	0.3–9.4
Thiazolidinedione	3.6 (3.1–7.1)	2.8–13.6
Insulin	5.3 (5.1–6.8)	4.7–11.7
Calcium channel blocker	20.4 (19.8–20.9)	19.2–22.9
ACEi or ARB	34.6 (34.0–35.8)	33.0–39.1
$\beta$ -Blocker	10.5 (9.9–11.0)	8.2–13.1
Vasodilator	4.8 (4.4–5.2)	4.0–5.4
Diuretics	12.8 (10.8–15.5)	10.2–17.2
Acetaminophen or tramadol	2.2 (1.7–2.4)	1.0–2.9
Nonsteroidal anti-inflammatory drug	3.1 (3.0–3.2)	2.8–3.4
Febuxostat	0.5 (0–1.3)	0–1.7
Allopurinol	0.7 (0.7–0.8)	0.4–0.9
Statin	47.6 (37.0–53.3)	24.0–63.0
Ezetimibe	4.7 (3.0–8.6)	0–16.8
Fibrate	2.5 (2.2–3.0)	1.9–3.5
Antiplatelet	38.4 (33.9–41.1)	31.2–43.9
Warfarin	1.8 (1.1–2.4)	0.9–2.6
Direct oral anticoagulants	0.2 (0–1.8)	0–2.5
Calcium-based phosphate binder	0.3 (0.3–0.3)	0.3–0.6
Non-calcium-based phosphate binder	0 (0–0)	0–0.01

ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.